Evidence map›Paper›PMID 36997321›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2023

The importance of including the C-terminal domain of PTP1B

Andrea Coronell-Tovar, Francisco Cortés-Benítez, Martin González-Andrade

Open access · goldAbstract read
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Andrea Coronell-TovarDepartamento de Bioquímica, Facultad de Medicina, Laboratorio de Biosensores y Modelaje molecular, Universidad Nacional Autónoma de México, Ciudad de México, México.ORCID 0000-0002-0165-4108
Francisco Cortés-BenítezDepartamento de Sistemas Biológicos, División de Ciencias Biológicas y de la Salud, Universidad Autónoma Metropolitana-Xochimilco (UAM-X), Ciudad de México, México.ORCID 0000-0002-3954-8220
Martin González-AndradeDepartamento de Bioquímica, Facultad de Medicina, Laboratorio de Biosensores y Modelaje molecular, Universidad Nacional Autónoma de México, Ciudad de México, México.ORCID 0000-0002-8910-3035
Universidad Nacional Autónoma de México · MXUniversidad Autónoma Metropolitana · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present work, we studied the inhibitory and kinetic implications of classical PTP1B inhibitors (chlorogenic acid, ursolic acid, suramin) using three enzyme constructs (

Indexed as

Enzyme InhibitorsHypoglycemic AgentsKineticsMolecular Docking SimulationProtein Tyrosine Phosphatase, Non-Receptor Type 1SuraminUrsolic AcidEnzyme InhibitorsHypoglycemic AgentsProtein Tyrosine Phosphatase, Non-Receptor Type 1SuraminUrsolic AcidDiabetes mellitus PTP1B1-400docking PTP1Binhibidors PTP1Bkinetic assay

Identifiers

PMID36997321
PMCPMC10064822
OpenAlexW4361261100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.